Policosanol
Summary
Policosanol's cholesterol evidence splits by who ran the trials. A meta-analysis of 22 studies (1,886 people) found lower LDL, with larger effects in Cuban studies, but independent trials in Germany, the US and Canada found no effect, even at 80 mg a day. Overall evidence is mixed (grade C).
Key facts
- LDL and total cholesterol: lowered in pooled trials, no effect in independent trials (mixed, C)[1][2][3][4]
- More than 80 trials were run mostly by a single research institute; the meta-analysis found Cuban studies reported larger effects[2][1]
- None of the three independent trials cited here names an industry funder in its PubMed record; the German JAMA trial notes that the earlier positive trials were run mostly by a single research institute[2][3][4]
- 4 graded human outcomes on this page
- October 10, 2026
How it works
ProposedPolicosanol has been proposed to lower cholesterol, but a kinetics trial and independent outcome trials did not confirm a lipid-lowering effect in humans, so the mechanism remains unproven.[2][3][4]
What the human research says
Human trials only, one row per outcome. The form column shows what each trial actually tested. Grades follow our evidence-grading policy.
| Outcome | Effect | Grade | Best evidence | PMID |
|---|---|---|---|---|
| LDL and total cholesterol (pooled trials) | Mixed | Grade C | Meta-analysis · n = 1,886 · 2018 Adults with dyslipidemia (22 studies) Form: Sugar cane policosanol · Dose: Varied; effects were not proportional to dose · Duration: Varied across studies Pooled results showed lower total cholesterol (95% CI -0.87 to -0.30 mmol/L) and LDL (95% CI -1.02 to -0.40 mmol/L) and higher HDL versus placebo, with no change in triglycerides or weight. Heterogeneity was high, Cuban studies reported larger effects than others, and there was no dose-response. | 28730734 (opens PubMed)Source [1] |
| LDL cholesterol in hypercholesterolemia | No effect | Grade C | RCT · n = 143 · 2006 Patients with hypercholesterolemia or combined hyperlipidemia (lipid clinics and GPs, Germany) Form: Cuban sugar cane policosanol · Dose: 10, 20, 40 or 80 mg per day · Duration: 12 weeks LDL fell by no more than 10% in any group, with no significant difference from placebo and no dose-response; total, HDL and VLDL cholesterol, triglycerides and Lp(a) were also unchanged. Policosanol was well tolerated. | 16705107 (opens PubMed)Source [2] |
| LDL cholesterol in mild hypercholesterolemia | No effect | Grade D | RCT · n = 40 · 2006 Healthy community-dwelling adults with mild hypercholesterolemia (US) Form: Sugar cane policosanol · Dose: 20 mg per day · Duration: 8 weeks No significant difference in LDL change between policosanol and placebo; total and HDL cholesterol, triglycerides and C-reactive protein were also unchanged. | 17158441 (opens PubMed)Source [3] |
| Blood lipids in hypercholesterolemia | No effect | Grade D | Crossover RCT · n = 21 · 2006 Healthy hypercholesterolemic volunteers (Canada) Form: Authentic Cuban sugar cane policosanol in margarine · Dose: 10 mg per day · Duration: 28 days per phase No significant difference from placebo in total, LDL or HDL cholesterol or triglycerides. | 17093150 (opens PubMed)Source [4] |
Forms
Studied doses
Doses studied in human trials ranged from 10 mg per day for 28 days to 80 mg per day for 12 weeks.[4][2]
Interactions
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Who should be careful
- People relying on it instead of prescribed cholesterol care
- Independent trials up to 80 mg/day found no LDL lowering.[2][3][4]
- People on many medications
- Interaction data are absent from the trials cited here.[2]
Talk to your pharmacist or clinician before starting a supplement, especially if you take prescription medicines.
Safety
Policosanol was well tolerated in trials; the main problem is lack of independent evidence that it works.
How to read the label
- Label dose vs clinical doseTrials used 10 to 80 mg per day; higher doses did not work better in the German trial.[2]
- Source matters to claimsPositive results came mostly from Cuban studies; the Cuban mixture itself failed in an independent Canadian trial.[1][4]
- Combination productsPolicosanol is often sold with red yeast rice or berberine; results for those combinations do not show what policosanol does alone.[1]
Cost per studied dose, without the sales pitch
Compare any product you already have by the amount it delivers, not by capsule count or front-of-pack weight.
Cost per studied dose
Enter the price, servings and the amount per serving from your label.
Frequently asked questions
Does policosanol lower cholesterol?
The evidence conflicts: pooled trials found lower LDL, mostly driven by Cuban studies, while independent trials found no effect.[1][2][3]
Does a higher dose work better?
No. In a 12-week German trial, 10, 20, 40 and 80 mg/day all failed to lower LDL versus placebo.[2]
Is Cuban policosanol different?
A Canadian trial tested the authentic Cuban mixture at 10 mg/day and found no effect on blood lipids.[4]
Is policosanol safe?
It was well tolerated without serious adverse events at up to 80 mg/day for 12 weeks.[2]
Sources
- [1]Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials.. Mol Nutr Food Res, 2018. meta-analysis
- [2]Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.. JAMA, 2006. RCT
- [3]Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial.. Am J Clin Nutr, 2006. RCT
- [4]Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons.. Am J Clin Nutr, 2006. crossover-RCT
What changed
- First draft. Every PMID checked against NCBI E-utilities esummary (title and year taken from the record) and abstracts read for the cited rows.
- Adversarial review pass: every evidence row re-read against its whole PubMed abstract. Official sources: no NIH ODS or NCCIH page covers policosanol. Industry ties: no funding statements in PubMed for the cited trials and none are in PMC; the JAMA abstract notes earlier trials came mostly from a single research institute. Not used: meta-analyses whose abstracts were not reviewed in full for this batch (15767233, 38185399). Retraction, expression-of-concern, erratum and withdrawn checks on all cited PMIDs: none flagged. Page set indexable.